JHOP - March 2018 Vol 8, No 1

The World Health Organization’s pain ladder for cancer recommends opioids for the treatment of moderate-to-severe pain in patients with cancer, and is a mainstay of cancer pain therapy.

Drug containers are defined in USP 797 based on the type of the container and the environment in which the container is opened. Vials are further divided into 2 categories: single-dose or multiple-dose.

A 20-year-old part of legislation, Section 114 of the Food and Drug Administration Modernization Act of 1997 (FDAMA), represents the primary regulatory structure for how drug manufacturers can distribute and use pharmacoeconomic information in the promotion of their drugs.

Anaplastic oligodendroglioma is a malignant neoplasm of the central nervous system characterized by the disease-defining 1p/19q codeletion and atypical histologic features indicating aggressive tumor biology.

For patients diagnosed with cancer, the annual incidence of VTE is approximately 20%, and the risk for VTE in this patient population is estimated to be 7 times higher than in the general population.

The combination of brentuximab vedotin and ibrutinib was well-tolerated and resulted in an overall response rate of 69%, a complete response rate of 46%, and a disease control rate of 100% in patients with relapsed/refractory Hodgkin lymphoma.
In patients with relapsed/refractory, aggressive non-Hodgkin lymphoma (NHL), use of prophylactic tocilizumab may reduce the incidence of severe cytokine release syndrome but not neurologic events in patients treated with chimeric antigen receptor T-cell therapy.
In a pooled analysis of 370 patients with relapsed/refractory mantle-cell lymphoma, treatment with ibrutinib for a median follow-up of 3.5 years resulted in 26% being progression-free and 45% still alive, with manageable toxicity.

In a retrospective cohort analysis of the largest series of patients with mantle-cell lymphoma (MCL) in which real-world economic burden data have been reported, the substantial economic burden of MCL was quantified, with inpatient admissions and office visits as the largest drivers of total costs for patients treated with rituximab, cyclophosphamide, doxorubicin, and vincristine; bendamustine and rituximab; and rituximab, and prescription drug costs as the largest component of total costs for patients receiving ibrutinib.

Page 1 of 2
Results 1 - 10 of 15